Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2024-10-23
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients with Severe Aortic stenosis undergoing TAVR using Myval Transcatheter Heart Valve that meet all inclusion criteria and any exclusion criteria will be able to participate in this study if they sign the informed consent. Electrocardiogram, echocardiogram and computed tomography will be performed to patients at different time points (Baseline, post-procedure, discharge, 30 days and 1 year post procedure) and their parameters will be added into a dedicated REDCAP database.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Left Septal or Deep Septal Pacing to Prevent Pacing-induced Cardiomyopathy
NCT06474819
UMBRELLA - Incidence of Arrhythmias in Spanish Population With a Medtronic Implantable Cardiac Defibrillator (ICD) Implant
NCT01561144
Study of Personalized Allocation of Defibrillators in Non-ischemic Heart Failure (SPANISH-1)
NCT06055504
Clinical Assessment of Essential Remote Monitoring Functions in Pacemakers
NCT05165095
Clinical and Device Functional Assessment of Real World ICD Patients
NCT02341768
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Objectives:
1. To evaluate the incidence of conduction defects and the need of pacemaker implantation post-procedure, at discharge, at 30 days and at 1 year post Myval transcatheter heart valve deployment.
2. To evaluate the factors determining in-hospital and late (at 30 days and 1 year) conduction defects post Myval transcatheter heart valve.
Description of the study protocol:
* Patients meeting the inclusion and exclusion criteria will be enrolled after taking informed consent. The baseline data and electrocardiogram (ECG), echocardiogram and computed tomography parameters will be added into a dedicated REDCAP database.
* TAVR will be performed as per the standard procedure using Myval Transcatheter Heart Valve.
* The ECG parameters post procedure, at discharge, at 30 days and at 1 year post-procedure will be noted using the REDCAP database.
* Based on these ECG parameters, analysis will be done to look for mean variations of PR and QRS segments, atrio-ventricular block, bundle branch block or need for pacemaker from baseline to post-procedure, at discharge, at 30 days and at 1 year post procedure.
* Echocardiogram parameters at 30 days (optional) and at 1 year post procedure will be noted using the REDCAP database.
* Statistical analysis will be done using IBM SPSS Statistics and R software.
Study duration:
* Inclusion stage: Patients will be recruited during the index procedure; if the patient meets all the inclusion criteria and any exclusion criteria and accepts to participate. ECG, echocardiogram and computed tomography will be done at baseline and the relevant information will be entered into the electronic database.
* In-hospital stage: Postprocedural and predischarge ECGs will be obtained and all the required clinical information will be gathered before discharge.
* Follow up stage: Clinical follow-up will be performed at 30 days and at 1 year post procedure, and the required ECG parameters will be obtained. At the 30-day follow-up, echocardiographic variables will be collected if the centers are available to perform echocardiograms or if an echocardiogram has been performed to the patients for other reasons within the determined period. In the 1-year follow-up, echocardiographic variables collected by clinical practice will be recorded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with Severe Aortic Valve Stenosis
All patients with Severe Aortic Valve Stenosis undergoing TAVR using Myval Transcatheter Heart Valve
TAVR
TAVR procedure using Myval Transcatheter Heart Valve
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TAVR
TAVR procedure using Myval Transcatheter Heart Valve
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with Severe Aortic stenosis undergoing TAVR using Myval Transcatheter Heart Valve.
Exclusion Criteria
* Patients unable or unwilling to follow up for pre and post procedure clinical assessments and investigations.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Meril Life Sciences Pvt. Ltd.
INDUSTRY
Hospital Clínico Universitario de Valladolid
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ignacio J. Amat Santos
Coordinator of Interventional Cardiology Unit
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Clínico Universitario de Valladolid
Valladolid, Valladolid, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PS-24-22-C
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.